Lower Price For Tecentriq In ES-SCLC Secures Coverage In England
Hot on the heels of recommending Roche’s drug for triple negative breast cancer, HTA body NICE today said the product should also be used for the first-line treatment of extensive-stage small-cell lung cancer.
You may also be interested in...
Roche’s Tecentriq has been rejected by health technology assessment body NICE for use in small-cell lung cancer on the National Health Service. The move follows an earlier knockback for the drug in PD L1-positive triple-negative breast cancer.
Bavencio, Taltz, Cosentyx, and Opdivo plus Yervoy were this week also the subject of final recommendations from the health technology assessment body, NICE, on whether or not they should be used on the National Health Service for certain indications.
Janssen and UK health technology assessment body NICE are being urged to sit down together and agree a suitable price for using Zytiga as a first-line treatment for advanced prostate cancer.